Vor Biopharma Statistics
Total Valuation
Vor Biopharma has a market cap or net worth of $1.23 billion. The enterprise value is $751.17 million.
| Market Cap | 1.23B |
| Enterprise Value | 751.17M |
Important Dates
The last earnings date was Friday, October 30, 2026, before market open.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vor Biopharma has 61.43 million shares outstanding. The number of shares has increased by 682.04% in one year.
| Current Share Class | 61.43M |
| Shares Outstanding | 61.43M |
| Shares Change (YoY) | +682.04% |
| Shares Change (QoQ) | +9.88% |
| Owned by Insiders (%) | 1.93% |
| Owned by Institutions (%) | 66.01% |
| Float | 42.54M |
Valuation Ratios
The trailing PE ratio is 0.66.
| PE Ratio | 0.66 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.55 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.50
| Current Ratio | 13.50 |
| Quick Ratio | 13.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -27.45% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -32.11% |
| Weighted Average Cost of Capital (WACC) | 14.27% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $17.81M |
| Employee Count | 76 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.36% in the last 52 weeks. The beta is 1.83, so Vor Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.83 |
| 52-Week Price Change | -11.36% |
| 50-Day Moving Average | 20.53 |
| 200-Day Moving Average | 17.39 |
| Relative Strength Index (RSI) | 51.83 |
| Average Volume (20 Days) | 811,388 |
Short Selling Information
The latest short interest is 7.45 million, so 12.12% of the outstanding shares have been sold short.
| Short Interest | 7.45M |
| Short Previous Month | 7.81M |
| Short % of Shares Out | 12.12% |
| Short % of Float | 17.50% |
| Short Ratio (days to cover) | 5.69 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -147.71M |
| Pretax Income | 1.35B |
| Net Income | 1.35B |
| EBITDA | -147.58M |
| EBIT | -147.71M |
| Earnings Per Share (EPS) | $30.51 |
Balance Sheet
The company has $481.55 million in cash and $2.81 million in debt, with a net cash position of $478.74 million or $7.79 per share.
| Cash & Cash Equivalents | 481.55M |
| Total Debt | 2.81M |
| Net Cash | 478.74M |
| Net Cash Per Share | $7.79 |
| Equity (Book Value) | -137.17M |
| Book Value Per Share | -2.23 |
| Working Capital | 454.18M |
Cash Flow
In the last 12 months, operating cash flow was -$119.17 million and capital expenditures -$507,000, giving a free cash flow of -$119.68 million.
| Operating Cash Flow | -119.17M |
| Capital Expenditures | -507,000 |
| Depreciation & Amortization | 126,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -119.68M |
| FCF Per Share | -$1.95 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vor Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -682.04% |
| Shareholder Yield | -682.04% |
| Earnings Yield | 152.41% |
| FCF Yield | -9.83% |
Analyst Forecast
The average price target for Vor Biopharma is $39.00, which is 94.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $39.00 |
| Price Target Difference | 94.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 19, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 19, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |